What's new? Log in Free sign up

Filing search / Inhibrx Biosciences, Inc. / "Antitrust"

Search information

Inhibrx Biosciences, Inc.

Companies

"Antitrust"

Keywords

SEC filings

Source

Export list of results

Export a CSV file of filings or unique companies (up to first 5,000 results).

Download list of filings Download list of companies

21 results

Newest first Best match first

INBX Inhibrx Biosciences, Inc.

Inhibrx Reports First Quarter 2024 Financial Results

date of the Merger is expected to occur on May 30, 2024. As previously disclosed, the waiting period under the Hart-Scott-Rodino Antitrust

INBX Inhibrx Biosciences, Inc.

Quarterly report

to be satisfied as a result of failure to obtain antitrust clearance. The Company and Parent filed notification of the proposed Merger with the Federal … Trade Commission and the Department of Justice under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, or the HSR Act. The applicable waiting

9 May 24

4:04pm

INBX Inhibrx Biosciences, Inc.

Proxy related to merger

Agreement by stockholders of the Company, receipt of regulatory approval under the HSR Act and other applicable antitrust laws, the accuracy … if the Merger is not consummated due to the failure of certain conditions to be satisfied as a result of failure to obtain antitrust clearance. Expenses

INBX Inhibrx Biosciences, Inc.

Additional proxy soliciting materials

of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the “HSR Act”). The Company and Sanofi each

INBX Inhibrx Biosciences, Inc.

of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the “HSR Act”). The Company and Sanofi each

28 Feb 24

9:10am

Additional proxy soliciting materials

my2ch1bsb xxes797j

Inhibrx Announces Sale of INBRX-101 to Sanofi for an aggregate value of up to $2.2B

9bers33y0bvf4pkvfg28

Inhibrx Announces Sale of INBRX-101 to Sanofi for an aggregate value of up to $2.2B

d06sezhmpx7ao9q3hw

Inhibrx Announces Sale of INBRX-101 to Sanofi for an aggregate value of up to $2.2B

criegxeq8fhamqlfdvc

IPO registration

27 Jul 20

8:47pm

r707vk63v a7elfq

Draft registration statement

IPO registration

slvs62guja ztax

IPO registration

IPO registration

IPO registration

skfhits7syrqhkvcp

IPO registration

Draft registration statement (amended)

5r0exshsr376a1emxr5v

Draft registration statement (amended)

1yzlukanxmjlhk6 jh

Draft registration statement (amended)

Prev
1
2
Next

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.